Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug. The patient did not experience any symptoms, and the injury resolved after discontinuation of the drug, Pfizer said in a statement. After reviewing all...
Civil rights work is slowing as Trump dismantles the Education Department, agency data showsData from the Education Department shows the pace at which it resolves civil rights complaints has slowed as the Trump administration dismantles the agencyJuly 18, 2025
- yesterday, 9:57 PM
- abcnews.go.com
- 0
No comments